爱思唯尔MDL公司的核心医药、化工客户群之中，半数用户已取得Isentris授权许可

美国商业资讯2007年1月10日加利福尼亚州圣拉蒙消息——

爱思唯尔MDL公司（Elsevier MDL）宣布，MDL(R) Isentris(R)系统全面升级，实现信息和软件应用产品与科学家工作流的集成。MDL Isentris 2.0具有数百项新功能，用户还会发现，产品的部分性能改进了，很有意义。使用新版产品，制药、生物技术和生命科学领域的机构可以更好地管理数据，降低拥有成本，加快工作流程，简化信息访问和信息报告，从而把研发效率提高到全新的水平。

爱思唯尔MDL公司总裁兼首席执行官Lars Barfod说，“过去的15年里，MDL(R) ISIS一直都是业内的标准，而MDL Isentris 2.0在功能、性能、潜力方面都大大超越了ISIS。

“可视化的化学反应规划器等独特新功能给科学家的日常工作流提供了更好的帮助。由于性能大幅提高，Isentris将带来更丰富的价值；不管是小型实验室还是在全球各地设立机构的大型研发实验室，都将从中受益。利用标准化的开发工具，研发机构可以按照自己的需求，自行定制系统。我们的大客户纷纷改用Isentris，充分利用这些优势。”

基本上，全球各大制药公司、生物技术企业、化工企业、研究所均采用MDL软件。近期，又有几家一流的企业评估了Isentris 2.0软件，随后即定购了这套新一代的系统。至此，爱思唯尔MDL公司30家重点客户之中，已有15家采用了Isentris系统。

雪兰诺公司（Serono）资深科学家Dominique Swinnen博士看了预先展示的软件，评论道：“Isentris 2.0看起来很有潜力。这套软件用户界面非常友好，给我留下了深刻印象。化学反应规划功能也让我眼前一亮。利用这个功能，可以探索前体化学反应的步骤，快速制订化学反应规划；这看起来很有用，在合成准备过程中，能替我们节约大量时间。”

Isentris 2.0正式版软件曾在大型数据库（包含的化学反应超过500万种，化学结构数据超过2000万条）上运行，性能稳定。软件支持化学反应快速搜索，与之前采用的组件型（cartridge-based）搜索引擎相比，性能有了显著改善；某些情况下，搜索速度甚至要快100倍。目前，使用Isentris浏览广域网，速度比ISIS快15倍；科学家把科学数据导入微软Excel的时候，速度比ISIS快了6倍；数据复制、剪切、排序时，速度是ISIS的2倍。Isentris软件支持几百人同时使用一台中型服务器。

使用Isentris时，科学家只需输入一条查询指令，就能搜索多个数据库；而且，无需信息技术辅助支持，就能保存复杂的搜索，之后重新使用，还可以建立个人信息视图。科学家能以更快的速度查找信息，探究结构－活动关系，与他人协作，研究科学假设，形成独到深入的见解，从而找到充分的依据，做出合理的决策。

对于机构来说，能用Isentris来处理大量的工作，处理各类数据类型，应对全球研发网络的压力，并提高投资回报率，降低信息技术成本。利用Isentris软件中预先建立的开发模块，信息技术部门能够运用微软.NET技术，快速创建自定制的科学应用软件。信息技术部门可为科学家提供自助式数据访问服务，提供稳定易用的应用程序，从而减少服务支持的工作负荷。此外，用户还可以统一访问内部专利数据源和商业数据源，这项便利显著改善了工作流，提高了效率。

如需了解详细情况，请访问：www.mdl.com 。可索取产品白皮书。

关于爱思唯尔MDL公司

爱思唯尔MDL公司（Elsevier MDL）提供信息学、数据库和工作流解决方案，可提高科学家决策的速度和水平，从而加快生命科学领域的成功研发。世界各地的研究人员依靠爱思唯尔MDL公司获取可靠的创新型发现信息学软件解决方案和服务，爱思唯尔400种化学和生命科学杂志及相关产品则进一步丰富了服务内容。如需了解详细情况，请访问：www.mdl.com 。爱思唯尔（Elsevier）公司是世界领先的出版商，提供科技和医学信息产品和服务。如需了解详细情况，请访问：www.elsevier.com 。爱思唯尔公司隶属里德?爱思唯尔集团公众有限公司（Reed Elsevier Group plc），该集团是全球一流的出版商和信息提供商。里德?爱思唯尔公司股票代码为REN（Euronext阿姆斯特丹证券交易所）、REL（伦敦证券交易所）、RUK和ENL（纽约证券交易所）。如需了解详细情况，请访问：www.reedelsevier.com 。

MDL和Isentris是MDL信息系统有限公司（MDL Information Systems, Inc.，“爱思唯尔MDL公司”）在美国的注册商标。保留一切权利。本文提及的其它各类商标属其各自所有人财产。

联系方式：爱思唯尔MDL公司 营销与沟通事务高级总监 Jean Holt，925-543-5400 j.holt@mdl.com

(BW)(CA-ELSEVIER-MDL)(RUK)(ENL)(REL.L) MDL(R) Isentris(R) 2.0 Offers Significant R&D Advantage

50% of Elsevier MDL's Top Pharmaceutical and Chemical Customers Have Licensed Isentris

SAN RAMON, Calif.--(BUSINESS WIRE)--Jan. 10, 2007--

Elsevier MDL has unveiled a significant upgrade to the MDL(R) Isentris(R) system for integrating information and software applications into scientists' workflows. MDL Isentris 2.0 features hundreds of new capabilities and demonstrable and meaningful performance improvements that give pharmaceutical, biotech and life sciences organizations unequaled ability to improve R&D productivity through better data management, lowered cost of ownership, faster workflow processes and easier information access and reporting.

"MDL Isentris 2.0 offers features, performance and potential well beyond MDL(R) ISIS, the industry standard for the past 15 years," said Lars Barfod, President and CEO of Elsevier MDL.

"Unique new features such as a visual reaction planner offer scientists better day-to-day workflow support. Dramatic performance improvements strengthen the value of Isentris from small to global multi-site R&D labs. And standardized development tools make it easy for organizations to customize systems to meet their needs. More and more of our major customers are migrating to Isentris to capitalize on these advantages."

MDL software is used at virtually every major pharmaceutical company, and at biotechnology, chemical and research institutions around the world. Following recent evaluations of Isentris 2.0, several more leading companies have purchased the new-generation system, bringing the number of top 30 Elsevier MDL customers that have adopted Isentris to 15.

Dr. Dominique Swinnen, a Senior Scientist at Serono who viewed a prerelease, commented: "Isentris 2.0 looks very promising. I was really impressed with how user-friendly it was and especially with the reaction planning functionality. The ability to explore precursor reaction steps and quickly build reaction plans looks very useful and could save us a lot of time during our synthesis preparation."

The Isentris 2.0 release features proven performance on databases of over 5 million reactions and 20 million structures. Reaction fast search gives substantial performance improvements over previous cartridge-based search engines, up to 100 times faster in some cases. Isentris now offers up to 15 times faster browsing over wide area networks than ISIS, and allows scientists to load scientific data into Microsoft Excel as much as six times faster, and copy, paste and sort the data twice as fast. Isentris can support hundreds of simultaneous users on a single mid-sized server.

Isentris lets scientists search multiple databases with a single query, save and reuse sophisticated searches and create personal data views without IT assistance. Scientists can find information faster, explore structure-activity relationships, collaborate, pursue hypotheses and gain insight for informed, intelligent decisions.

For organizations, Isentris is designed to handle the massive loads, diverse data types and pressure of global R&D networks, while offering higher ROI and lower IT costs. Pre-built development components in Isentris enable IT groups to rapidly create custom scientific applications using Microsoft .NET technology. IT groups can reduce support workloads by providing scientists with self-service data access and consistent, easy to learn applications. And integrated access to internal proprietary and commercial data sources offers significant workflow and efficiencies.

For more information visit www.mdl.com . A whitepaper is available on request.

About Elsevier MDL

Elsevier MDL provides informatics, database and workflow solutions that accelerate successful scientific R&D by improving the speed and quality of scientists' decision making. Researchers around the world depend on Elsevier MDL for innovative and reliable discovery informatics software solutions and services augmented by 400 Elsevier chemistry and life sciences journals and related products. For more information, visit www.mdl.com. Elsevier is a world-leading publisher of scientific, technical and medical information products and services. For more information, visit www.elsevier.com. Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange). For more information, visit www.reedelsevier.com .

MDL and Isentris are registered trademarks of MDL Information Systems, Inc. ('Elsevier MDL') in the United States. All rights reserved. All other trademarks mentioned in this document are the property of their respective owners.

CONTACT: Elsevier MDL Jean Holt, 925-543-5400 Sr. Director, Marketing & Communications j.holt@mdl.com